The Value of Epicardial Adipose Tissue for Patients Treated with Percutaneous Coronary Intervention: A Systemic Review and Meta-analysis

Background: Recently, some clinical researches have shown epicardial adipose tissue to play a pivotal role in prognosis for patients treated with percutaneous coronary intervention (PCI), but the results are still controversial. A systematic review and meta-analysis was conducted to investigate the value of epicardial adipose tissue for the prognosis of patients treated with PCI. Method: A systematic search was performed using PubMed, Web of Science, and the Cochrane Library for studies evaluating the association of EAT and patients treated with PCI published up to January 2023. The Newcastle-Ottawa Scale (NOS) was used to assess the quality of the studies. Meta-analysis was performed using Review Manager V.5.3. Result: Thirteen studies enrolling 3683 patients were eventually included in our study. The thickness or volume of EAT measured were significantly higher in the ISR group compared to those in the non-ISR group (the standard mean difference of 0.34, 95% CI, 0.18-0.49, p<0.0001; I2=36%). The incidence of no-reflow was significantly higher in the thicker EAT group compared to the thin EAT group (pooled relative ratio 1.52, 95% CI 1.29-1,80, p<0.0001; I2 =0%). Thicker EAT was significantly associated with MACEs (pooled relative ratio 1.50, 95% 1.18-1.90, p=0.008). A lower EAT volume was associated with larger infarct size in STEMI patients treated with primary PCI (standard mean difference -5.45, 95% CI -8.10, -2.80; p<0.0001; I2=0%). Conclusion: In summary, our systemic review and meta-analysis suggests that high EAT is related to a significantly increased risk of non-reflow, MACEs, and decreased infarct size in patients with CAD treated with PCI. This paradox phenomenon demonstrates that the quality of EAT may play a more important role than the sole thickness or volume of EAT.